| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.0 |
| Profit before tax | 3.9 | -8.8 |
| Net income | 3.9 | -8.8 |
| EPS (diluted, $ a share) | $0.05 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +273.3% |
|---|
10-Q filed with the SEC, NASDAQ: CLNN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Clene Inc.: key numbers
- Share price
- $3.66Close, Nov 16
- Market cap
- $52.7M
- Shares outstanding
- 14.4MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Clene Inc.
All →Clene Financial Results
Clene Inc. reported third quarter 2026 financial results, highlighting the submission of a New Drug Application (NDA) to the FDA for CNM-Au8 in ALS. The company ended the quarter with $9.9 million in cash, bolstered by a $4.0 million registered direct offering completed in September, providing a runway through mid-first quarter 2027.
“Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS. People living with ALS urgently need additional treatment options, and we appreciate the FDA’s constructive engagement throughout this process. We look forward to working closely with the Agency during its pending review. We believe CNM-Au8 has the capacity to restore and protect neuronal health and function and improve survival.”
Rob Etherington, President and CEO of Clene
Clene Business Update
Clene Inc. entered into a subaward amendment with NYU for the fourth year of a previously announced NIH grant, providing up to $7.2 million in funding. The grant supports an Expanded Access Program for the company's CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS). This represents the final year of a total $45.1 million four-year grant awarded under the ACT for ALS Act.
- Counterparty
- New York University
- Term
- Sept 2026 to Aug 2027
Clene Business Update
Clene Inc. has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes, with the company also preparing for a confirmatory Phase 3 RESTORE-ALS study.
- Counterparty
- FDA
Clene Capital Raise of $4M
Clene Inc. entered into a securities purchase agreement for a $4.0 million registered direct offering of 1,219,513 shares of common stock at $3.28 per share. The offering was led by the company's Chairman and CEO alongside existing investors to fund regulatory filings for its lead drug candidate, CNM-Au8, and general corporate purposes. The proceeds are expected to extend the company's cash runway through mid-first quarter 2027.
- Value
- $4M
- Counterparty
- David Matlin, Kensington Capital Holdings, and other existing stockholders